Elementis maintains competitive strength through its expertise in rheology modifiers, antiperspirant actives, and functional additives that enhance the performance and flow characteristics of customers' products. The company has grown through strategic acquisitions including SummitReheis ($362M, 2017) and Mondo Minerals ($600M, 2018), establishing leadership positions in specialty chemistry while maintaining presence across North America, Europe, and Asia.
Cyborg Score Rationale
Elementis demonstrates solid market positioning as a FTSE 250 constituent with established businesses serving resilient end-markets (personal care, coatings, industrials). However, the company faces cyclical exposure to construction and manufacturing demand, modest revenue growth (~3.5% in 2023), and ongoing market competition. Recent acquisition history shows strategic ambition, though integration execution remains a key variable.
Top Insights
Portfolio spans three complementary segments (Specialty Products, Surfactants, Chromium) with exposure to defensive markets like personal care and home care
Major acquisitions in 2017-2018 significantly expanded personal care and talc-based additives businesses; integration success critical to value realization
Revenue of $738.3M in 2023 with modest 3.5% growth indicates mature business facing cyclical headwinds
FTSE 250 constituent with LSE listing provides strong UK investor base and institutional visibility